App aims to boost breast cancer drug adherence
NCT ID NCT06905301
First seen Feb 05, 2026 · Last updated May 20, 2026 · Updated 13 times
Summary
This study looks at whether a mobile app can help people with hormone-receptor-positive, HER2-negative stage II or III breast cancer stick to their prescribed treatment of ribociclib plus an aromatase inhibitor. About 240 participants will either use the app or not, and researchers will compare how many in each group continue their therapy for 12 months. The app provides information on relapse risks and managing side effects to support adherence.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Novartis Investigative Site
RECRUITINGPskov, Russia, 180000, Russia
-
Novartis Investigative Site
RECRUITINGMoscow, 115304, Russia
-
Novartis Investigative Site
RECRUITINGSaint Petersburg, 194017, Russia
-
Novartis Investigative Site
RECRUITINGSaint Petersburg, 194291, Russia
-
Novartis Investigative Site
RECRUITINGSaint Petersburg, 197758, Russia
-
Novartis Investigative Site
RECRUITINGSestroretsk, 197706, Russia
-
Novartis Investigative Site
RECRUITINGUfa, 450054, Russia
Conditions
Explore the condition pages connected to this study.